Shanlee Davis
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 16 | 2025 | 72 | 6.420 |
Why?
| | Turner Syndrome | 10 | 2025 | 65 | 5.130 |
Why?
| | Trisomy | 4 | 2025 | 78 | 2.670 |
Why?
| | Sex Chromosome Aberrations | 9 | 2025 | 68 | 2.510 |
Why?
| | Sex Chromosome Disorders | 3 | 2025 | 28 | 2.330 |
Why?
| | Neurodevelopmental Disorders | 3 | 2025 | 218 | 2.170 |
Why?
| | Testosterone | 6 | 2025 | 418 | 2.020 |
Why?
| | XYY Karyotype | 4 | 2025 | 23 | 1.840 |
Why?
| | Chromosomes, Human, X | 5 | 2025 | 77 | 1.330 |
Why?
| | Mosaicism | 4 | 2024 | 74 | 1.300 |
Why?
| | Oxandrolone | 3 | 2018 | 8 | 1.230 |
Why?
| | Mental Disorders | 4 | 2025 | 1144 | 1.110 |
Why?
| | Child Development | 2 | 2025 | 504 | 1.090 |
Why?
| | Sex Chromosome Disorders of Sex Development | 3 | 2025 | 17 | 1.090 |
Why?
| | Cardiovascular Diseases | 5 | 2025 | 2103 | 0.960 |
Why?
| | Puberty | 4 | 2024 | 154 | 0.830 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 58 | 0.790 |
Why?
| | Body Composition | 4 | 2025 | 706 | 0.770 |
Why?
| | Child | 28 | 2025 | 22562 | 0.740 |
Why?
| | Testis | 3 | 2018 | 158 | 0.700 |
Why?
| | Monosomy | 1 | 2021 | 12 | 0.690 |
Why?
| | Registries | 4 | 2024 | 2227 | 0.680 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 39 | 0.660 |
Why?
| | Sex Chromosomes | 4 | 2025 | 46 | 0.660 |
Why?
| | Inhibins | 1 | 2020 | 42 | 0.650 |
Why?
| | Ovarian Reserve | 1 | 2020 | 16 | 0.650 |
Why?
| | Dyslipidemias | 1 | 2022 | 178 | 0.640 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 121 | 0.640 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 40 | 0.630 |
Why?
| | Phenotype | 7 | 2025 | 3184 | 0.630 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 353 | 0.630 |
Why?
| | Androgens | 2 | 2018 | 190 | 0.620 |
Why?
| | Prevalence | 7 | 2025 | 2817 | 0.620 |
Why?
| | Case-Control Studies | 6 | 2025 | 3604 | 0.570 |
Why?
| | Adolescent | 21 | 2025 | 22326 | 0.540 |
Why?
| | Aneuploidy | 5 | 2024 | 88 | 0.540 |
Why?
| | Electronic Health Records | 3 | 2025 | 1144 | 0.520 |
Why?
| | Male | 32 | 2025 | 70910 | 0.500 |
Why?
| | Female | 29 | 2025 | 76624 | 0.480 |
Why?
| | Body Height | 1 | 2017 | 203 | 0.470 |
Why?
| | Humans | 44 | 2025 | 142526 | 0.470 |
Why?
| | Infertility, Male | 1 | 2015 | 62 | 0.460 |
Why?
| | Adipose Tissue | 1 | 2019 | 649 | 0.450 |
Why?
| | Child, Preschool | 15 | 2025 | 11634 | 0.440 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.440 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 39 | 0.400 |
Why?
| | Hypertension | 1 | 2022 | 1257 | 0.390 |
Why?
| | Double-Blind Method | 4 | 2025 | 2007 | 0.380 |
Why?
| | Veterans | 1 | 2024 | 1531 | 0.360 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 210 | 0.360 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1083 | 0.350 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1772 | 0.340 |
Why?
| | Obesity | 2 | 2022 | 3027 | 0.320 |
Why?
| | Infant, Newborn | 5 | 2025 | 6324 | 0.320 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5700 | 0.310 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5270 | 0.310 |
Why?
| | Infant | 7 | 2025 | 9908 | 0.290 |
Why?
| | Estradiol | 2 | 2023 | 524 | 0.290 |
Why?
| | Autism Spectrum Disorder | 2 | 2025 | 423 | 0.240 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 26 | 0.240 |
Why?
| | Cohort Studies | 4 | 2025 | 5858 | 0.230 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 437 | 0.230 |
Why?
| | Morbidity | 2 | 2024 | 321 | 0.230 |
Why?
| | Epilepsy | 1 | 2010 | 370 | 0.230 |
Why?
| | Karyotype | 2 | 2023 | 17 | 0.220 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 98 | 0.220 |
Why?
| | Meta-Analysis as Topic | 1 | 2025 | 169 | 0.220 |
Why?
| | United Kingdom | 1 | 2025 | 325 | 0.210 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 76 | 0.210 |
Why?
| | Blood Glucose | 1 | 2014 | 2304 | 0.210 |
Why?
| | Y Chromosome | 1 | 2023 | 11 | 0.210 |
Why?
| | Adult | 11 | 2025 | 39715 | 0.210 |
Why?
| | Young Adult | 8 | 2024 | 13878 | 0.200 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 6 | 0.190 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 28 | 0.180 |
Why?
| | Oxadiazoles | 1 | 2022 | 36 | 0.180 |
Why?
| | Comorbidity | 2 | 2025 | 1678 | 0.180 |
Why?
| | Phosphocreatine | 1 | 2021 | 44 | 0.180 |
Why?
| | Mental Health | 2 | 2025 | 767 | 0.180 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 80 | 0.170 |
Why?
| | Quality of Life | 2 | 2024 | 3064 | 0.170 |
Why?
| | Body Mass Index | 2 | 2020 | 2406 | 0.170 |
Why?
| | Genitalia | 1 | 2021 | 34 | 0.170 |
Why?
| | Transgender Persons | 1 | 2024 | 203 | 0.170 |
Why?
| | Gonadotropins | 1 | 2020 | 40 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 310 | 0.160 |
Why?
| | Waist Circumference | 1 | 2020 | 136 | 0.160 |
Why?
| | Genetic Association Studies | 1 | 2021 | 375 | 0.160 |
Why?
| | Hypogonadism | 1 | 2020 | 92 | 0.150 |
Why?
| | Prognosis | 2 | 2019 | 4112 | 0.150 |
Why?
| | Developmental Disabilities | 2 | 2016 | 290 | 0.150 |
Why?
| | Magnetoencephalography | 1 | 2020 | 158 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 119 | 0.150 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.150 |
Why?
| | Failure to Thrive | 1 | 2019 | 28 | 0.150 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 318 | 0.150 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 485 | 0.150 |
Why?
| | Testicular Hormones | 1 | 2018 | 9 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 616 | 0.150 |
Why?
| | United States | 3 | 2025 | 15447 | 0.140 |
Why?
| | Face | 1 | 2020 | 174 | 0.140 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 29 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 197 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1426 | 0.140 |
Why?
| | Growth Disorders | 1 | 2019 | 87 | 0.140 |
Why?
| | Mentors | 1 | 2020 | 214 | 0.140 |
Why?
| | Triglycerides | 1 | 2020 | 512 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 283 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 150 | 0.130 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 328 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 594 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 879 | 0.120 |
Why?
| | Speech Disorders | 1 | 2016 | 31 | 0.120 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 952 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 567 | 0.120 |
Why?
| | Risk | 1 | 2019 | 905 | 0.120 |
Why?
| | Language Development Disorders | 1 | 2016 | 39 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 886 | 0.120 |
Why?
| | Truth Disclosure | 1 | 2016 | 49 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2016 | 81 | 0.120 |
Why?
| | Algorithms | 1 | 2023 | 1791 | 0.120 |
Why?
| | Research | 1 | 2019 | 434 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1728 | 0.120 |
Why?
| | Body Weight | 1 | 2019 | 997 | 0.110 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 143 | 0.110 |
Why?
| | Mitochondria | 1 | 2021 | 973 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 252 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 148 | 0.110 |
Why?
| | Muscle Strength | 1 | 2017 | 332 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2074 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 622 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2927 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2021 | 1229 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2388 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2251 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2980 | 0.090 |
Why?
| | Hospitalization | 2 | 2024 | 2293 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 473 | 0.090 |
Why?
| | Biomarkers | 2 | 2022 | 4207 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2022 | 11298 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1773 | 0.070 |
Why?
| | Cognition | 1 | 2017 | 1249 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2875 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2761 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1255 | 0.070 |
Why?
| | Middle Aged | 3 | 2025 | 35049 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1391 | 0.060 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 197 | 0.060 |
Why?
| | Aged | 1 | 2025 | 25117 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2492 | 0.060 |
Why?
| | Syndrome | 2 | 2020 | 378 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2561 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 16 | 0.050 |
Why?
| | Europe | 1 | 2024 | 410 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 104 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 213 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 53 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
| | Androstenedione | 1 | 2022 | 11 | 0.050 |
Why?
| | Amines | 1 | 2022 | 38 | 0.050 |
Why?
| | Thiazoles | 1 | 2022 | 134 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 147 | 0.040 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 191 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 835 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 398 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 87 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1496 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 468 | 0.040 |
Why?
| | Suicidal Ideation | 1 | 2024 | 552 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2023 | 16626 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 279 | 0.030 |
Why?
| | Peer Group | 1 | 2020 | 250 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 234 | 0.030 |
Why?
| | Health Status | 1 | 2023 | 822 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3819 | 0.030 |
Why?
| | Universities | 1 | 2020 | 451 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 2053 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 165 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1501 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2018 | 304 | 0.030 |
Why?
| | Suicide | 1 | 2024 | 673 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2826 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 346 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 633 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 866 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 181 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 375 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 430 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 407 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 551 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1096 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1661 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 937 | 0.020 |
Why?
| | Parents | 1 | 2019 | 1450 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7113 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1087 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1552 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1503 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5994 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|